C4 Therapeutics CMO Adam Crystal resigns; Hagop Youssoufian named interim CMO

C4 Therapeutics, Inc.

Adam S. Crystal, M.D., Ph.D., resigns as CMO effective Feb 24, 2023 to pursue a head of R&D opportunity elsewhere.
Crystal will provide transitional consulting services on an as-needed basis until Sep 1, 2023.
Hagop Youssoufian, M.D., appointed interim CMO effective Feb 24, 2023; permanent search underway.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Adam S. Crystal

Chief Medical Officer

CCCC · C4 Therapeutics, Inc.

Effective: 2023-02-24
Filed: February 2, 2023, 6:59 PM ET

On January 30, 2023, Adam S. Crystal, M.D., Ph.D., informed us of his intent to resign from his position as the Chief Medical Officer of C4 Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam S. Crystal resigned as Chief Medical Officer at C4 Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On January 30, 2023, Adam S. Crystal, M.D., Ph.D., informed us of his intent to resign from his position as the Chief Medical Officer of C4 Therapeutics, Inc.

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-002041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.